BibTex RIS Kaynak Göster

Mide Karsinomunda Prediktif Faktörler

Yıl 2016, Cilt: 26 Sayı: 1, 1 - 7, 01.01.2016

Asude Aksoy

Öz

Amaç: Serum albumin, albumin-globulin oranı AGR , nötrofil/lenfosit N/L değerlerinin mide kanseri hastalarında sağkalım üzerine etkileri araştırıldı.Gereç ve Yöntem: Ön çalışma niteliğindeki bu çalışmaya kemoterapi değerlendirmesindeki 46 hastanın biyokimyasal parametreleri retrospektif olarak arşiv kayıtlarından alındı. AGR=Albumin/Total Protein-Albumin formülüyle AGR değerleri hesaplandı. Büyükten küçüğe doğru sıralanıp, Receiver Operating Characteristic ROC analiziyle AGR düşük-yüksek olarak değerlendirildi. Albumin ve N/L oranları da benzer şekilde gruplandırıldı.Bulgular: AGR’ nin ROC analiziyle tespit edilen cut-off değeri; 1.295 % 62.5 duyarlılık, % 50 özgüllük idi. Kaplan-Meier metoduyla yüksek AGR grubunda düşük AGR grubuna göre daha uzun ortalama genel sağkalım OS tespit edildi. Sırasıyla 27 ± 21 aya karşı 26 ± 26 ay , p: 0.706, % 95 CI: 0.295-0.791 . ROC analiziyle albumin için cut-off değeri; 4.05 mg/dl % 50 duyarlılık, % 58.5 özgüllük idi. Kaplan-Meier metoduyla düşük albumin seviyeli olan grupda yüksek albumin seviyeli olan grupa göre daha uzun OS tespit edildi. OS; 30 ± 26 aya karşı 22 ± 21 ay , p: 0.524, % 95 CI:0.195-0.660 dı, sırasıyla. ROC analizine göre N/L’ nin cut-off değeri: 2.445 % 50 duyarlılık, % 60.5 özgüllük idi. Kaplan-Meier metoduyla OS’ si yüksek olan N/L grubunda düşük olan gruba göre daha uzun olarak tespit edildi 32 ± 29 aya karşı 23 ± 19 ay , p:0.965, % 95 CI: 0.247-0.748 idi. Logistic regression analizi ile AGR, N/L, albumin düzeyleri ile mortalite ve OS arasında istatitiki anlamlı ilişki tespit edilmemiştir.Sonuç: AGR, N/L, albumin düzeyleri mide kanserli hastalardaki mortaliteyi, sağkalımı öngörmede tek başlarına yeterli parametreler olmayabilirler. Vaka sayılarının arttırılmasıyla daha net sonuçlar elde edilebilinir

Anahtar Kelimeler

AGR N/L albumin mide kanseri sağkalım mortalite

Kaynakça

  • Jemal A, Bray F, Center MM, et al. Global Cancer Statistics. CA Canc Clin 2011; 61: 69-90.
  • World Health Organization.International Agency for rese- arch on cancer. Globocan Turkey. 2012.
  • World Health Organization. Cancer. Accesed 11 Aug 2013. Available from: URL: http://www.who.int/mediacentre/fa- ctsheets/fs297/en/
  • Chen K, Xu XW, Mou YP, et al. Systematic review and me- ta-analysis of laparoscopic and open gastrectomy for ad- vanced gastric cancer. World J Surg Oncol 2013; 11: 182.
  • Wang W, Li Z, Tang J, et al. Laparoscopic versus open total gastrectomy with D2 dissection for gastric cancer: a me- ta-analysis. J Cancer Res Clin Oncol 2013; 139: 1721-34.
  • Fujitani K. Overview of adjuvant and neoadjuvant therapy for resectable gastric cancer in the East. Dig Surg 2013; 30: 119-29.
  • Ronellenfitsch U, Schwarzbach M, Hofheinz R, et al. GE Adenocarcinoma Metaanalysis Group. Perioperative che- mo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal jun- ction, and lower esophagus. Cochrane Database Syst Rev 2013; 5.
  • Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in advanced gastric cancer: a systemic review and meta-analy- sis based on aggregate. J Clin Oncol 2006; 24: 2903-9.
  • Gospodarowicz M, Mackillop W, O’Sullivian B. Prognostic factors in clinical decision making: the future. Cancer 2001; 98: 1866-95.
  • Amini N, Spolverato G, Kim Y, et al. Clinicopathological features and prognosis of gastric cardia adenocarcinoma: A multi-institutional U.S. study. J Surg Oncol 2015; 3:285-92.
  • Gaspar MJ, Arribas I, Coca MC et al. Prognostic value of carcinoembryonic antigen, CA19-9, and CA 72-4 in gastric carcinoma. Tumour Biol 2001; 22: 318-22.
  • Wobbes T, Thomas CMG, Segers MFG, et al. Evaluation of seven tumors markers in the pretreatments of patients gast- ric carcinoma. Cancer 1992; 69: 2036-41.
  • McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care 2009; 12: 223-6.
  • Forones NM, Mandowsky SV, Lourenço LG. Serum levels of interleukin-2 and tumor necrosis factor-alpha correlate to tumor progression in gastric cancer. Hepatogastroente- rology 2001; 48:1199-201.
  • Goldwasser P, Felman J. Association of serum albumin and mortality risk. J Clin Epidemiol 1997; 50: 693-703.
  • OkamuraT, Hayakawa T, Kadowaki T, et al. A combination of serum low albumin and above-average cholesterol level was associated with excess mortality. J Clin Epidemiol 2004; 57: 1188-95.
  • Knaus WA, Wagner DP, Draper EA, et al. The APACHE III prognostic system risk prediction of hospital mortalityfor critically ill hospitalized adults. Chest 1991; 100: 1619-36.
  • Oñate-Ocaña LF Aiello-Crocifoglio V, Gallardo-Rincón D., et al. Serum albumin as a significant prognostic factor for patients with gastric carcinoma. Ann Surg Oncol 2007; 14: 381-9.
  • Tateishi R, Yoshida H, Shiina S, et al. Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients. Gut 2005; 54: 419-25.
  • Azab B, Kedia S, Shah N, et al. The value of the pretreatment albumin/globulin ratio in predicting the long term survival in colorectal cancer. Int J Colorectal Dis 2013; 28:1629-36.
  • Azab BN, Bhatt VR, Vonfrolio S, et al. Value of the pretre- atment albumin to globulin ratio in predicting long-term mortality in breast cancer patients. Am J Surg 2013; 206: 764-70.
  • Shen JJ, Niu WN, Zhou M, et al. Association of Epstein Barr Virus A73 Gene Polymorphism with Nasopharyngeal Car- cinoma. Genet Test Mol Biomarkers 2014; 1:2
  • Friedman JM, Stavas MJ, C melak AJ. Clinical and scientific impact of human papillomavirus on head and neck cancer. World J Clin Oncol 2014; 4:781-91.
  • Mazarico E, Gómez-Roig MD, Miñano J, et al. Relationship of human papilloma virus multiple genotype infection with patient’s age and type of cervical lesion. Eur J Gynaecol On- col 2014; 35:378-81.
  • Coussesns LM, Werb Z. Inflamation and cancer. Nature 2002; 420: 860-7.
  • Paesmans M, Sculier JP, Libert P, et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univa- riate and multivariate analyses including recursive partiti- oning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. J Clin Oncol 1995; 13:1221-30.
  • Kobayashi N, Usui S, Kikuchi S, et al. Preoperative lymp- hocyte count is an independent prognostic factor in no- de-negative non-small cell lung cancer. Lung Cancer 2012; 75:223-7.
  • Wang S, Zhang Z, Fang F, et al. The neutrophil/lymphocy- te ratio is an independent prognostic indicator in patients with bone metastasis. Oncol Lett 2011; 2: 735-40.
  • Kao SC, Pavlakis N, Harvie R, et al. High blood neutrop- hil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res 2010; 16: 5805-13.
  • Kishi Y, Kopetz S, Chun YS, et al. Blood neutrophil-to-ly- mphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy Ann Surg Oncol 2009; 16: 614-22.
  • Kunisaki C, Takahashi M, Ono HA, Oshima T. Inflammati- on-based prognostic score predicts survival in patients with advanced gastric cancer receiving biweekly docetaxel and s-1 combination chemotherapy. Oncology 2012; 83:183-91.

Yıl 2016, Cilt: 26 Sayı: 1, 1 - 7, 01.01.2016

Asude Aksoy

Öz

Introduction: Serum albumin, albumin-globulin ratio AGR , neutrophil/lymphocyte N / L levels in patients with gastric carcinoma were investigated on survival impact. Methods: This study was planned as a pilot study. Biochemical parameters of 46 patients were obtained from archive retrospectively. AGR levels were calculated by AGR =albumin/Total Protein- Albumin formula. They were sorted by descending, AGR was evaualted with lower and upper by using ROC. Albumin and N/L were divided similarly.Results: AGR cut-off value was 1.295 with ROC, in ROC: 0.543 62.5% sensitivity, 50% specificity . The mean overall survival’s OS detected 20 months in lower AGR group, 28 ± 21 months in upper AGR group. A longer OS was detected in upper AGR group by Kaplan-Meier p = 0.706, 95% CI: 0.295-0.791 . According to ROC of level albumin’s cut-off value was 4.05 mg/dL in the ROC: 0.545, 50% sensitivity, 58.5% specificity . The OS was detected 22 ± 21 months, in lower albumin group, 30 ± 26 months in upper albumin group. A longer OS was detected in upper albumin group by Kaplan-Meier p=0.524, 95% CI:0.195-0.660 . According to ROC, cut-off value of N/L was 2.445 in ROC:0.495, 50% sensitivity, 60.5% specificity . The OS was detected 32 ± 29 months in upper N/L group, 23 ±19 months in lower N/L group. A longer OS was determined in upper N/L group by Kaplan-Meier p=0.965, 95% CI:0.247-0.748 . There were no statistical significant differences regarding prediction of survival, mortality for patient’s AGR, N/L, albumin levels by logistic regression analysis.Discussion: AGR, N/L, albumin levels may be not alone sufficient for prediction of survival, and mortality parameters in gastric cancer. It can be obtained more accurate results by increasing the number of cases

Anahtar Kelimeler

AGR N/L albumin gastric carcinoma survival mortality

Kaynakça

  • Jemal A, Bray F, Center MM, et al. Global Cancer Statistics. CA Canc Clin 2011; 61: 69-90.
  • World Health Organization.International Agency for rese- arch on cancer. Globocan Turkey. 2012.
  • World Health Organization. Cancer. Accesed 11 Aug 2013. Available from: URL: http://www.who.int/mediacentre/fa- ctsheets/fs297/en/
  • Chen K, Xu XW, Mou YP, et al. Systematic review and me- ta-analysis of laparoscopic and open gastrectomy for ad- vanced gastric cancer. World J Surg Oncol 2013; 11: 182.
  • Wang W, Li Z, Tang J, et al. Laparoscopic versus open total gastrectomy with D2 dissection for gastric cancer: a me- ta-analysis. J Cancer Res Clin Oncol 2013; 139: 1721-34.
  • Fujitani K. Overview of adjuvant and neoadjuvant therapy for resectable gastric cancer in the East. Dig Surg 2013; 30: 119-29.
  • Ronellenfitsch U, Schwarzbach M, Hofheinz R, et al. GE Adenocarcinoma Metaanalysis Group. Perioperative che- mo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal jun- ction, and lower esophagus. Cochrane Database Syst Rev 2013; 5.
  • Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in advanced gastric cancer: a systemic review and meta-analy- sis based on aggregate. J Clin Oncol 2006; 24: 2903-9.
  • Gospodarowicz M, Mackillop W, O’Sullivian B. Prognostic factors in clinical decision making: the future. Cancer 2001; 98: 1866-95.
  • Amini N, Spolverato G, Kim Y, et al. Clinicopathological features and prognosis of gastric cardia adenocarcinoma: A multi-institutional U.S. study. J Surg Oncol 2015; 3:285-92.
  • Gaspar MJ, Arribas I, Coca MC et al. Prognostic value of carcinoembryonic antigen, CA19-9, and CA 72-4 in gastric carcinoma. Tumour Biol 2001; 22: 318-22.
  • Wobbes T, Thomas CMG, Segers MFG, et al. Evaluation of seven tumors markers in the pretreatments of patients gast- ric carcinoma. Cancer 1992; 69: 2036-41.
  • McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care 2009; 12: 223-6.
  • Forones NM, Mandowsky SV, Lourenço LG. Serum levels of interleukin-2 and tumor necrosis factor-alpha correlate to tumor progression in gastric cancer. Hepatogastroente- rology 2001; 48:1199-201.
  • Goldwasser P, Felman J. Association of serum albumin and mortality risk. J Clin Epidemiol 1997; 50: 693-703.
  • OkamuraT, Hayakawa T, Kadowaki T, et al. A combination of serum low albumin and above-average cholesterol level was associated with excess mortality. J Clin Epidemiol 2004; 57: 1188-95.
  • Knaus WA, Wagner DP, Draper EA, et al. The APACHE III prognostic system risk prediction of hospital mortalityfor critically ill hospitalized adults. Chest 1991; 100: 1619-36.
  • Oñate-Ocaña LF Aiello-Crocifoglio V, Gallardo-Rincón D., et al. Serum albumin as a significant prognostic factor for patients with gastric carcinoma. Ann Surg Oncol 2007; 14: 381-9.
  • Tateishi R, Yoshida H, Shiina S, et al. Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients. Gut 2005; 54: 419-25.
  • Azab B, Kedia S, Shah N, et al. The value of the pretreatment albumin/globulin ratio in predicting the long term survival in colorectal cancer. Int J Colorectal Dis 2013; 28:1629-36.
  • Azab BN, Bhatt VR, Vonfrolio S, et al. Value of the pretre- atment albumin to globulin ratio in predicting long-term mortality in breast cancer patients. Am J Surg 2013; 206: 764-70.
  • Shen JJ, Niu WN, Zhou M, et al. Association of Epstein Barr Virus A73 Gene Polymorphism with Nasopharyngeal Car- cinoma. Genet Test Mol Biomarkers 2014; 1:2
  • Friedman JM, Stavas MJ, C melak AJ. Clinical and scientific impact of human papillomavirus on head and neck cancer. World J Clin Oncol 2014; 4:781-91.
  • Mazarico E, Gómez-Roig MD, Miñano J, et al. Relationship of human papilloma virus multiple genotype infection with patient’s age and type of cervical lesion. Eur J Gynaecol On- col 2014; 35:378-81.
  • Coussesns LM, Werb Z. Inflamation and cancer. Nature 2002; 420: 860-7.
  • Paesmans M, Sculier JP, Libert P, et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univa- riate and multivariate analyses including recursive partiti- oning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. J Clin Oncol 1995; 13:1221-30.
  • Kobayashi N, Usui S, Kikuchi S, et al. Preoperative lymp- hocyte count is an independent prognostic factor in no- de-negative non-small cell lung cancer. Lung Cancer 2012; 75:223-7.
  • Wang S, Zhang Z, Fang F, et al. The neutrophil/lymphocy- te ratio is an independent prognostic indicator in patients with bone metastasis. Oncol Lett 2011; 2: 735-40.
  • Kao SC, Pavlakis N, Harvie R, et al. High blood neutrop- hil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res 2010; 16: 5805-13.
  • Kishi Y, Kopetz S, Chun YS, et al. Blood neutrophil-to-ly- mphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy Ann Surg Oncol 2009; 16: 614-22.
  • Kunisaki C, Takahashi M, Ono HA, Oshima T. Inflammati- on-based prognostic score predicts survival in patients with advanced gastric cancer receiving biweekly docetaxel and s-1 combination chemotherapy. Oncology 2012; 83:183-91.
Toplam 31 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Yazarlar

Asude Aksoy Bu kişi benim

Yayımlanma Tarihi 1 Ocak 2016
Yayımlandığı Sayı Yıl 2016 Cilt: 26 Sayı: 1

Kaynak Göster

Vancouver Aksoy A. Mide Karsinomunda Prediktif Faktörler. Genel Tıp Derg. 2016;26(1):1-7.


Genel Tıp Dergisi Creative Commons Atıf-GayriTicari 4.0 Uluslararası Lisansı (CC BY NC) ile lisanslanmıştır.